Settlement Structure: Claims Made
Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.
The plaintiffs in this lawsuit allege that Cephalon and Teva Pharmaceuticals violated federal and state antitrust laws by delaying the sale of generic, low-cost versions of Provigil.Docket Number:
Company: Teva Pharmaceutical Industries
Filing Deadline: April 13, 2017
Class Period: June 24, 2006 to March 31, 2012
Objection Deadline: April 14, 2017
Exclusion Deadline: April 14, 2017
Final Approval Hearing: July 25, 2017Proof of Purchase: Eligibility:
This settlement includes all persons residing in the states of Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia who purchased and/or paid for Provigil or generic versions of Provigil (modafinil) for consumption by themselves or their families during the period from June 24, 2006 through March 31, 2012.Typical Settlement Amount:
Settlement shares will be distributed based upon how much you paid for Provigil or other generic options compared to what other consumers paid.
Total Settlement Amount: $35,000,000Class Representative Proposed Incentive Fee:
Ohio Attorney General’s Office
Claim Form: Consumer Claim Form
Case Name: State of New York, et al., v. Cephalon, Inc. et al.
Settlement Website: AG Provigil Settlement Website
State AG Provigil Settlement
c/o A.B. Data, Ltd.
P.O. Box 173026
Milwaukee, WI 53217